; (B) opening a public docket for the submission of public comments; or (C) other means, as the Secretary determines appropriate. (c) Selection of drugs for updating If the Secretary determines, with respect to a covered drug, that the available evidence is sufficient to meet the standards under section 505 for adding information to the labeling or modifying information in the labeling regarding the use of the covered drug, the Secretary may initiate the process under subsection (d). (d) Initiation of the process of updating If the Secretary determines that labeling changes are appropriate for a selected drug pursuant to subsection (c), the Secretary shall provide notice to the holders of approved applications for a generic version of such drug that— (1) summarizes the findings supporting the determination of the Secretary that the available evidence is sufficient to meet the standards under section 505 for modifying the labeling of the drug pursuant to subsection (c); (2) states the modifications to the labeling that should be made in order to reflect such determination (including, as applicable, modifications to add the relevant accepted use to the labeling of the drug as an additional indication for the drug); and (3) states whether the statement under paragraph (2) applies to the selected drug as a class of drugs or only as to a specific drug product. (e) Response to notification Within 30 days of receipt of notification provided by the Secretary pursuant to subsection (d), the holder of an approved application shall— (1) agree to change the approved labeling to reflect the modifications the Secretary has determined are appropriate